AUTHORS
Alberto De Iaco, PhD, Donghui Li, PhD2, Ninad Kumbhojkar, PhD3, Jessica Desmond, MS4, Jeff Ann, PhD5, Rebecca Levy, MS6, Lorenzo Tozzi, PhD7, Mohit Gupta, PhD8, Rahul Palchaudhuri, PhD9, Z. Jane Wang, PhD10, Francesca Alvarez Calderon, MD, PhD11, Ulrike Gerdemann, MD12, Lev Gorfinkel, MD13, Kristin Rathje, MD14, Leslie Kean, MD, PhD15, Hari Pujar, PhD16, Michael C Holmes, PhD17, Cecilia Cotta-Ramusino, PhD18
AFFILIATIONS
1 Tessera Therapeutics, Somerville, Massachusetts, United States
2 Tessera Therapeutics, Somerville, Massachusetts, United States
3 Tessera Therapeutics, Somerville, Massachusetts, United States
4 Tessera Therapeutics, Somerville, Massachusetts, United States
5 Tessera Therapeutics, Somerville, Massachusetts, United States
6 Tessera Therapeutics, Somerville, Massachusetts, United States
7 Tessera Therapeutics, Somerville, Massachusetts, United States
8 Tessera Therapeutics, Somerville, Massachusetts, United States
9 Tessera Therapeutics, Somerville, Massachusetts, United States
10 Tessera Therapeutics, Somerville, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
16 Tessera Therapeutics, Somerville, Massachusetts, United States
17 Tessera Therapeutics, Somerville, Massachusetts, United States
18 Tessera Therapeutics, Somerville, Massachusetts, United States
ABSTRACT
Autologous ex vivo Chimeric Antigen Receptor (CAR) T-cell therapies are a powerful treatment option for relapsed and refractory leukemias and lymphomas. However, significant challenges may limit access to these therapies, including long vein-to-vein times for drug delivery, viral vector supply chain constraints, complex manufacturing processes, and high costs. While allogeneic CAR-T therapies are in clinical development, they have not yet matched the therapeutic efficacy of conventional autologous T-cell therapies, highlighting the need for effective same-day in vivo treatment strategies.
Gene Writers are designed to edit cellular genomes using RNA templates by harnessing the mechanism of target-primed reverse transcription (TPRT). These Gene Writers are designed to perform various editing reactions, from introducing gene-length DNA sequences to making single or multiple nucleotide substitutions. This approach is designed to achieve these edits by delivering all-RNA compositions to primary cells in vivo, potentially eliminating the need for viral vectors and DNA template-based genome editing methods.
Using T cell-targeted lipid nanoparticles (tLNPs), we co-delivered Gene Writer mRNA together with anti-CD19 CAR templates to non-stimulated human primary T cells in vitro, generating up to approximately 30% CAR+ T cells with robust functional activity. We next evaluated therapeutic efficacy in two humanized mouse models. A single administration of tLNPs encapsulating Gene Writer mRNA and an anti-CD19 CAR template in tumor-bearing mice generated ~25% CAR-T cells in vivo, and achieved complete tumor eradication. In a complementary CD34+ humanized mouse model, tLNP-mediated delivery of Gene Writer mRNA with anti-CD20 CAR template produced ~20% CD20 CAR+ T cells at peak and mediated complete and durable depletion of human B cells.
Finally, we administered tLNPs formulated with Gene Writer mRNA and an anti-CD20 CAR template to cynomolgus and rhesus macaques. Across multiple studies, a single administration at doses ranging from 0.1 to 0.02 mg/kg produced sustained B-cell depletion in peripheral blood and lymph nodes for up to 35 days in both NHP species. We then assessed the biodistribution of Gene Writer integration in the animal receiving the highest dose (0.1 mg/kg). No detectable Gene Writer integration events were observed in any of the 32 tissues examined outside of the intended T cells.
Collectively, these findings support our Gene Writing and proprietary tLNP delivery platforms, which combines all-RNA delivery with stable genomic integration, offering a potential path towards more scalable and accessible in vivo CAR-T therapies.
DISCLOSURES
Alberto De Iaco, PhD: No relevant conflicts of interest to declare.